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Background: Congenital hypothyroidism is often secondary to thyroid dysgenesis, including thyroid agenesis,
hypoplasia, ectopic thyroid tissue or cysts. Loss of function mutations in TSHR, PAX8, NKX2.1, NKX2.5 and FOXE1
genes are responsible for some forms of inherited congenital hypothyroidism, with or without hypoplastic thyroid.
The aim of this study was to analyse the PAX8 gene sequence in several members of the same family in order to
understand whether the variable phenotypic expression, ranging from congenital hypothyroidism with thyroid
hypoplasia to mild subclinical hypothyroidism, could be associated to the genetic variant in the PAX8 gene,
detected in the proband.
Methods: We screened a hypothyroid child with thyroid hypoplasia for mutations in PAX8, TSHR, NKX2.1, NKX2.5
and FOXE1 genes. We studied the inheritance of the new variant R133W detected in the PAX8 gene in the
proband’s family, and we looked for the same substitution in 115 Caucasian European subjects and in 26
hypothyroid children. Functional studies were performed to assess the in vitro effect of the newly identified PAX8
gene variant.
Results: A new heterozygous nucleotide substitution was detected in the PAX8 DNA-binding motif (c.397C/T,
R133W) in the proband, affected by congenital hypothyroidism with thyroid hypoplasia, in his older sister, displaying
a subclinical hypothyroidism associated with thyroid hypoplasia and thyroid nodules, in his father, affected by
hypothyroidism with thyroid hypoplasia and thyroid nodules, and his first cousin as well, who revealed only a
subclinical hypothyroidism. Functional studies of R133W-PAX8 in the HEK293 cells showed activation of the TG
promoter comparable to the wild-type PAX8.
Conclusions: In vitro data do not prove that R133W-PAX8 is directly involved in the development of the thyroid
phenotypes reported for family members carrying the substitution. However, it is reasonable to conceive that, in
the cases of transcriptions factors, such as Pax8, which establish several interactions in different protein complexes,
genetic variants could have an impact in vivo.
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Congenital hypothyroidism (CH) is a common disease with
a worldwide incidence of 1 in 3,000-4,000 newborns [1]. In
85% of the cases, CH is secondary to thyroid dysgenesis,
including thyroid agenesis, hypoplasia, ectopic thyroid tis-
sue or cysts [2].
Loss of function mutations of the thyrotropin receptor
(TSHR) are responsible for some forms of recessively
inherited congenital hypothyroidism, either with normal
or hypoplastic glands [3]. Other cases of thyroid dysgen-
esis may result from mutations in some of the transcrip-
tion factors genes involved in thyroid development, such
as PAX8, NKX2.1 (also known as TTF1), FOXE1 and
NKX2.5 [2,4-6].
Pax8 is a member of the large mammalian Pax protein
family, a group of important developmental regulators de-
fined by the presence of a highly conserved DNA-binding
motif of 128 amino acids, the so-called “paired-box do-
main”. This element is well conserved during evolution
and consists of two distinct structurally independent sub-
domains, each containing a helix-turn-helix motif, joined
by a linker region [7]. The N- and C- terminal subdomains
are called PAI and RED, respectively [8].
During mouse embryogenesis, PAX8 gene is expressed
in the developing thyroid, in the kidney and in several
areas of central nervous system [9-11]. In addition to its
role in thyroid development, Pax8 is an important regu-
lator of thyroid differentiation through the activation of
specific genes expression, namely thyroid peroxidase
(TPO) and thyroglobulin (TG) [12,13].
In humans, PAX8 gene maps to chromosome 2q12-
q14 and consists of at least ten exons [14]. So far, several
PAX8 mutations and a rare sequence variant have been
reported [2,15-27]. They have been mostly detected in
patients with normally located but hypoplastic thyroid
gland, often associated with renal anomalies, and in aFigure 1 Pedigree of the family discussed. The arrow indicates the prob
II-5, II-6, III-4, and III-5 were subject to DNA analysis and they did not carryfew patients with complete athyreosis [2,16-19,21]. The
aim of this report is to analyse PAX8 gene in members
of the same family with variable phenotypic expressivity:
from congenital hypothyroidism with thyroid hypoplasia,
to mild subclinical hypothyroidism, in order to establish
whether a correlation between variants in the PAX8 gene
and different phenotypes is present.
Methods
Subjects
In this study we analysed 9 members of a family with
history of hypothyroidism, 26 patients with congenital
hypothyroidism and 115 healthy subjects.
Patient III-2 (Figure 1), the proband, a male subject, was
born in 1983 after an uneventful pregnancy. The patient
was diagnosed as hypothyroid in the reference centre for
newborn screening programs of North-Eastern Italy. TSH
and total T4 values, assayed in dried blood spot collected
at 3–5 days of life by radioimmunoassay, were 281 mIU/L
(controls <10 mIU/L) and 18 nmol/L (controls >60 nmol/L),
respectively.
Serum investigations confirmed the diagnosis of con-
genital hypothyroidism (TSH 93 mIU/L and free T4 17
pmol/L, normal values 0.4-4.0 mIU/L and 10.3-24.5
pmol/L respectively), and substitution therapy with L-
thyroxine 37 μg daily was started at three weeks of life.
The dose was adjusted to 50 μg/d at four months of life,
and was stabilized at 75 μg/d when the infant was ten
months old. He is now assuming 125 μg daily. The ultra-
sound examination demonstrated a hypoplastic but
normally located thyroid gland. Abdomen ultrasound
investigation showed no abnormalities. His growth, renal
function (at blood tests), neuropsychological development
and IQ (measured several times and with different test
depending on the age) were normal. During one of the
follow-up examinations and after obtaining written informedand. The R133W carriers are evidenced in grey. The subjects II-2,
the R133W variant.
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from the patient and his parents in order to screen for muta-
tion in the PAX8, TSHR, FOXE1, NKX2.1, NKX2.5 genes.
Upon detection of the same PAX8 sequence variant
detected in the index case, subject II-3, father of the pro-
band, was submitted to endocrinological examination; at
that time he was 60 years old. Serum determinations evi-
denced TSH concentration of 20.5 mIU/L (normal values
0.4-4.0 mIU/L) and free T4 level of 9.4 pmol/L (n.v. 10.3-
24.5 pmol/L). Thyroid autoantibodies were negative and
serum thyroglobulin was in the normal range. Substitutive
therapy with L-thyroxine 50 μg daily was promptly
started. After four months of therapy, plasma TSH de-
creased to 7.39 mIU/L (n.v. 0.35-5.50 mIU/L) and free T4
raised to 14.7 pmol/L (n.v. 11.5-22.7 pmol/L). Substitutive
therapy was changed to 50–75 μg every other day, and
both serum TSH and free T4 returned within the corre-
sponding ranges of the reference population. Despite the
lack of substitutive therapy until the age of 60, the physical
and intellectual development was normal. He did not
present neurological alterations. Renal function was in the
normal range for age. Ultrasound examination revealed a
normally located thyroid gland with hypoplasia of the left
lobe (measuring 10 × 5 mm), and the presence of three
nodules with calcifications (measuring 15 × 16 mm) in the
right one. A fine needle aspiration biopsy was performed
on the right lobe. A moderate colloid amount and some
aggregates of thyroid cells with hypertrophic nucleus were
detected. Malignant cells search was negative. Thyroid
scintigraphy revealed poor uptake. The presence of the
isthmus was not reported on ultrasound examination, and
it was not on uptake scan.
Seven members of the same family (subjects II-2, II-5,
II-6, III-1, III-3, III-4, III-5) were asked to send us capil-
lary blood samples absorbed on paper (Schleicher &
Schuell 903 paper), in order to search for the same
PAX8 variant. Subject III-1, the proband’s sister, aged
30 years, revealed to be a carrier of the PAX8 sequence
variant. Her serum TSH was 6.85 mIU/L (n.v. 0.25-3.50
mIU/L) and serum free T4 was 16.9 pmol/L (n.v. 10.3-24.4
pmol/L). Thyroid autoantibodies were negative. Serum
thyroglobulin was 244.00 ng/mL (upper limit 60.00 ng/mL).
The ultrasound investigation evidenced a thyroid gland
located in the normal position, with isthmus agenesis,
hypoplastic left lobe and right one with three nodules.
A fine needle aspiration biopsy was performed on the
right lobe. No abnormalities were reported at the cyto-
logical analysis. Abdomen echography showed no anomal-
ies. No neurological or renal dysfunctions were evidenced.
Her condition was periodically monitored and L-thyroxine
therapy was no indicated, since her hypothyroidism
remained subclinical. As for the father (subject II-3),
the daughter (III-1) came to our attention undetected
from birth, because at the time of their birth newbornscreening for congenital hypothyroidism still had to be
instituted.
Patient III-3, cousin of the proband, showed to be a car-
rier of the PAX8 sequence variant too. His serum TSH
value is mildly elevated (4.66 mIU/L, n.v. 0.27-4.20 mIU/L)
with a fT4 in the normal range. Thyroid autoantibodies
were negative and serum thyroglobulin was 95.70 ng/mL
(upper limit 60.00 ng/mL). His thyroid function was
periodically checked, evidencing a persistent subclinical
hypothyroidism. At the moment he takes no therapy. He
was submitted to thyroid ultrasound that evidenced a nor-
mally located thyroid gland with both the lobes slightly re-
duced in size. No other clinical abnormalities were found.
Notably, he reported that his father (patient II-4, pro-
band’s uncle) was treated with L-thyroxine for one year
before cardiac surgery. He died of heart failure.
In all the other relatives reported in Figure 1 thyroid
function was evaluated and TSH, fT4 and fT3 values
were in the normal range. No relevant clinical alterations
were described for them. Given the family history, we
recommended to these unaffected family members a
periodic follow-up. At the moment, we have no informa-
tion of alterations in their thyroid function.
In order to exclude the occurrence of the new PAX8
genetic variant as a common polymorphism, 115 healthy
Caucasian European subjects have been screened for the
same substitution. They signed written informed consent
for the genetic analysis.
In addition, 26 patients with congenital hypothyroidism
followed at Pediatric Endocrinology Division of Verona
Hospital during 2011, were screened for the same substi-
tution, after their parents’ written consents were ob-
tained. All of them were older than fourteen and were in
L-thyroxine treatment from birth. Thirty-one per cent of
them did not present echographic alterations, 25% showed
thyroid hypoplasia, 31% ectopia and the remaining 13%
agenesis of the gland.
The study was conducted in compliance with the terms
of the Helsinki II Declaration and written informed con-
sent for the enrolment and for the publication of in-
dividual clinical details was obtained from patients or,
whenever participants were children, from their parents
or guardians.
In our country, namely Italy, this type of clinical study
does not require Institutional Review Board/Institutional
Ethics Committee approval to publish the results.
Genetic analysis
Genomic DNA was extracted from peripheral venous
blood on EDTA by means of the Gentra Puregene Blood
kit (QIAGEN S.p.A, Milan, Italy), following the manufac-
turer’s instructions.
Genomic DNA was extracted from the blood spot paper
cards by means of the QIAamp® DNA Micro kit (QIAGEN
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instructions.
We amplified by PCR all the exons of PAX8, TSHR,
FOXE1, NKX2.1, NKX2.5 genes by means of intronic
primers. Fragments were first analyzed by Denaturing
High Performance Liquid Chromatography on a WAVE
DNA Fragment Analysis System (Transgenomic, Omaha,
NE), and sequenced on an automated CEQ 8800 Genetic
Analysis System (Beckman Coulter GmbH, Germany)
whenever a sequence variation was suspected. PCR condi-
tions, partial denaturing temperature (tpd) for DHPLC
analysis and sequencing conditions for TSHR and PAX8
genes have been previously described [28]. For FOXE1,
NKX2.1 and NKX2.5 genes, sequencing conditions are
available upon request.Polyphen prediction
PolyPhen (=Polymorphism Phenotyping) is an automatic
tool for prediction of possible impact of an amino acid
substitution on the structure and function of a human
protein. This prediction is based on straightforward em-
pirical rules which are applied to the sequence, phylo-
genetic and structural information characterizing the
substitution [29]. PolyPhen-2 is a new development of
the popular PolyPhen tool and is available as freeware at
http://genetics.bwh.harvard.edu/pph2/ web site.Construction of the expression vector and functional
analysis
The wild-type PAX8 protein (WT-PAX8) was expressed
in the vector pcDNA3 as already described [20].
Human thyroglobulin promoter was cloned in the
pGL3 luciferase report vector (TG prom-pGL3), de-
signed to provide enhanced reporter gene expression.
TTF1-pcDNA3 and pCMV-HA-p300 expression vectors
have been previously described [20]. pRL-TK, expressing
Renilla luciferase activity, (Promega Corporation, Madison,
WI) was used as internal control vector.
Mutant harbouring the single nucleotide missense
substitution (R133W) was generated by site-directed
mutagenesis using the GeneTailor site-directed mutagen-
esis system (Invitrogen Life Technologies, Carlsbad, CA).
The accuracy of the recombinant construct was verified
by direct sequencing.
HEK293 cells were grown in DMEM supplemented with
2 mM L-glutamine, 25 mM D-glucose, 50 U/mL Penicil-
lin, 50 μg/mL Streptomycin and 10% FBS (Invitrogen Life
Technologies, Carlsbad, CA) and plated in 12-well plates
(2×10 [5] cells for well) for 24 h before transfection.
Transfection was carried out with FuGENE 6 reagent, fol-
lowing the manufacturer’s instructions (Roche Diagnostic
Corporation, Indianapolis, IN, USA), with a total amount
of plasmid DNA of 1170 ng per well.Cells were harvested 48 h later and analysed sequen-
tially for firefly and Renilla luciferase activities by Dual-
Luciferse Reporter Assay System (Promega Corporation,
Madison,WI). The luminescence production in cell ex-
tracts was assayed using the Lumino luminometer (Stratec
Electronic; GMBH, Birkenfeld, Germany). Light intensity
was quantified using a pre-produced standard curve and
was reported in relative light units (RLUs). The assay was
performed in triplicate.
Statistical analysis
Values of transcriptional activity of R133W mutant were
compared with respect to the values obtained for wild
type Pax8 using the Student two tails t-test. To test the
significance, the risk level (p) was set at 0.05.
Results
Genetic analysis
DHPLC analysis and direct sequencing of TSHR, FOXE1,
NKX2.1 and NKX2.5 genes in genomic DNA of the patient
III-2 revealed no variation compared to the NCBI Reference
Sequences NM_000369.2, NC_000009.11, NC_000014.8 and
NG_013340.1, respectively.
During DHPLC analysis, a nucleotide substitution was
suspected in the PAX8 fifth exon and its direct sequencing
revealed the presence of a heterozygous transition of cyto-
sine to thymine (C→T) at position 397 of the coding
sequence (NCBI Reference Sequence NM_003466.3),
leading to a change of a conserved arginine at codon 133
to tryptophan (c.397C/T, R133W) (Figure 2). The muta-
tion was detected in the paired domain, the highly con-
served PAX8 DNA-binding motif, at the end of the third
alpha helix of the RED subdomain. This sequence variant
was first detected in the propositus, affected by congenital
hypothyroidism with a hypoplastic thyroid. The same sub-
stitution was present at the heterozygous state in his father,
in his sister and in his first cousin, who evidenced mild
hypothyroidism the first, and subclinical hypothyroidism
the other two. In both the father and sister on the index
case, the morphology of the thyroid showed hypoplasia
and the presence of thyroid nodules.
We accessed the NCBI Single Nucleotide Polymorph-
ism database and R133W was not found as a common
variant. Moreover, the R133W variant was not present in
a screen of 115 Caucasian European subjects (230 con-
trol chromosomes), reducing the likelihood that this
substitution could represent a neutral common variant.
In addition, the PAX8 fifth exons of 26 hypothyroid chil-
dren were analysed and none carried the R133W variant.
PolyPhen prediction
The Polyphen Tool forecasted for the R133W variant a
hydrophobicity change at buried site. Accordingly, R133W
was predicted to be a pathogenic variant.
Figure 2 In the left side: DHPLC profiles of wild type (green) and mutated (brown) PAX8 exon 5. The partial denaturing temperature was
set at 61.3°C and the chromatographic parameters were obtained by means of the WAVEMaker software (Transgenomic, Omaha, NE), based on
the amplicon sequence [23]. In the right side: Sequencing electropherogram of exon 5. A heterozygous C→ T transition is shown where a Y is
reported, corresponding to nucleotide 397 of the PAX8 coding sequence (NCBI Reference Sequence NM_003466.3). The mutation replaces a
conserved arginine at position 133 with a tryptophan residue (R133W).
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pCMV-HA-p300 was cotransfected with expression vec-
tor carrying WT-PAX8 or R133W-PAX8, together with
an internal control (pRL-TK Renilla) and the TG prom-
pGL3 (Firefly). The firefly to Renilla luminescence activ-
ity ratios were calculated and compared between groups.
The transfection of WT-PAX8 together with 500 ng
pCMV-HA-p300 revealed a significant increase in the
TG promoter activity compared to WT-PAX8 alone
(p < 0.01, Figure 3, columns 2–3), and this in accord-
ance to literature [20,30]. R133W-PAX8, when transfected
with pCMV-HA-p300, showed a significant increased
TG promoter activity, to the same extent of WT-PAX8
(p < 0.01, Figure 3, columns 5–6 compared to 2–3).
Cotransfection of TTF1-pcDNA3 resulted in a synergistic
effect of p300 and the R133W-PAX8 or WT-PAX8 on the
TG promoter (Figure 3 columns 4 vs 7 showed no statis-
tical difference, 0.05 < p < 0.1).Figure 3 The intensity of luminescence production in HEK293 cells is
were normalized to the Renilla luciferase activity derived from cotransfecteDiscussion
The Pax8 transcription factor is required for mammalian
morphogenesis of the thyroid gland, and it is essential
for the thyrocite-specific promoter activation of the TPO
and TG genes [9-11]. In humans, PAX8 mutation car-
riers have been reported to be hypothyroids with thyroid
hypoplasia [2,15-27]. Most of the known mutations are
monoallelic and localized in the paired box domain. They
evidence a functional DNA-binding impairment, suggest-
ing that hypothyroidism could be secondary to PAX8
haploinsufficiency.
In the present report we describe different members of
the same family carrying the same PAX8 variant at the
heterozygous state: the R133W substitution, replacing the
last conserved arginine of the DNA-binding paired-box do-
main with a tryptophan residue, and characterized by a pre-
diction of likely being a damaging substitution. The family
members carrying the substitution evidence a remarkablereported in relative light units (RLUs). Firefly luciferase activities
d pRL-TK internal control vector (see text).
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associated with thyroid hypoplasia, to mild subclinical
hypothyroidism with thyroid hypoplasia and nodules.
In order to verify the actual role of the R133W variant
in the development of the thyroid phenotype, we carried
out in vitro functional studies in the TG promoter,
known to be a genetic target of the Pax8 transcription
factor. On the TG promoter, the Pax8 protein interacts
with several other transcription factors in the formation
of complexes targeting several regulatory regions [20].
The general transcriptional coactivator p300 has been
shown to be essential in mediating Pax8 activation on both
the TG and the rat thyroperoxidase (TPO) promoters. It
plays a crucial role in the functional synergism between
Pax8 and NKX2.1 in thyroid specific gene expression
[20,30]. In order to assess whether R133W mutation was
able to efficiently recruit p300 and assemble the transcrip-
tional coactivation complex [20], we employed HEK293
cells. These cells, indeed, are deficient in endogenous p300
because of expression of the adenovirus E1A protein
[30,31], which sequestrates p300 into the cytosol.
Functional studies of R133W-PAX8 in the HEK293
cells show comparable activation of the TG promoter of
both the mutated and the wild-type Pax8. Furthermore,
R133W-Pax8, similarly to the wild-type, is able to recruit
p300 to synergistically transactivate the TG promoter.
Evaluation of 282 alleles belonging to either healthy or
hypothyroid subjects revealed that R133W-PAX8 does
not seem to be a common polymorphism and therefore
it is probably a rare variant.
It is well known that persistent stimulation by in-
creased plasma TSH levels leads to thyroid proliferation
and often nodule formation [32,33]. This clinical obser-
vation could account for the similar phenotype of sub-
jects II-3 and III-1, evidencing thyroid nodules, and for
the substantial difference in the propositus, patient III-2,
who was treated from birth with substitutive therapy,
and displayed no thyroid nodules, at least so far.
It is well known in literature that often PAX8 gene
mutations display variable expressivity, and even the
same mutation gives rise to different clinical and bio-
chemical phenotypes among members of the same fam-
ily [16,18,19]. Our in vitro data does not prove that
R133W-PAX8 is directly involved in the development of
the phenotypes reported for the family members carriers
of the aminoacidic substitution and, in this view, it could
be a non influential polymorphism. However, since the
crystallographic data of the last 4 residues of the PAX8
paired domain, corresponding to the region where the
substitution R133W is located, still have to be completely
clarified [7,34,35], we cannot exclude that interactions
with other transcription factors could be responsible for
the variable phenotypic expressivity evidenced in the re-
ported family.Conclusions
Although in vitro data do not prove that R133W-PAX8
is directly involved in the development of the different
thyroid phenotypes reported for the heterozygous car-
riers of the same family, it is reasonable to conceive that
the substitution described could have an impact in vivo,
the condition where all the interactions with different
protein complexes actually take place. For transcription
factors such as Pax8, indeed, genetic, epigenetic and en-
vironmental factors are likely involved, and only a thor-
ough understanding of all the possible actors entangled
can deeply clarify the actual contribution of variant such
as the R133W-PAX8.
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